[Click e-Stock] "MFC Expands with Development of APIs for Improved Drugs"

On June 30, Hana Securities analyzed that MFC is expanding its portfolio of high value-added products through the development of active pharmaceutical ingredients (APIs) for improved drugs.

Kim Seona, a researcher at Hana Securities, explained, "MFC is developing APIs for improved drugs based on its capabilities in developing and producing APIs and key intermediates."

She added, "In the case of APIs for improved drugs, they can be used as a patent-avoidance strategy against original pharmaceutical company APIs," and noted, "They are more profitable compared to general generic APIs."

She emphasized, "Because these are high value-added products, we expect rapid sales growth," and stated, "The mid- to long-term sales plan is to achieve annual growth of 27.8%, reaching annual sales of KRW 55 billion by 2028."

Kim also predicted, "The development of exclusive new products and improved drugs through high-purity crystallization technology will play an important role in achieving growth targets."